Skip to main content
NCBI home page
Public Health Reports logoLink to Public Health Reports
. 2004 Mar-Apr;119(2):174–186. doi: 10.1177/003335490411900211

Prostate cancer incidence and mortality rates and trends in the United States and Canada.

Kathleen McDavid 1, Judy Lee 1, John P Fulton 1, Jon Tonita 1, Trevor D Thompson 1
PMCID: PMC1497609  PMID: 15192905

Abstract

OBJECTIVE: The purpose of this study was to compare prostate cancer incidence and mortality trends between the United States and Canada over a period of approximately 30 years. METHODS: Prostate cancer incident cases were chosen from the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Program to estimate rates for the United States white males and from the Canadian Cancer Registry for Canadian men. National vital statistics data were used for prostate cancer mortality rates for both countries, and age-adjusted and age-specific incidence and mortality rates were calculated. Joinpoint analysis was used to identify significant changes in trends over time. RESULTS: Canada and the U.S. experienced 3.0% and 2.5% growth in age-adjusted incidence from 1969-90 and 1973-85, respectively. U.S. rates accelerated in the mid- to late 1980s. Similar patterns occurred in Canada with a one-year lag. Annual age-adjusted mortality rates in Canada were increasing 1.4% per year from 1977-93 then fell 2.7% per year from 1993-99. In the U.S., annual age-adjusted mortality rates for white males increased 0.7% from 1969-1987 and 3.0% from 1987-91, then decreased 1.2% and 4.5% during the 1991-94 and 1994-99 periods, respectively. CONCLUSIONS: Recent incidence patterns observed between the U.S. and Canada suggest a strong relationship to prostate-specific antigen (PSA) test use. Clinical trials are required to determine any effects of PSA test use on prostate cancer and overall mortality.

Full Text

The Full Text of this article is available as a PDF (341.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Feuer E. J., Merrill R. M., Hankey B. F. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999 Jun 16;91(12):1025–1032. doi: 10.1093/jnci/91.12.1025. [DOI] [PubMed] [Google Scholar]
  2. Gann P. H. Interpreting recent trends in prostate cancer incidence and mortality. Epidemiology. 1997 Mar;8(2):117–120. [PubMed] [Google Scholar]
  3. Hankey B. F., Feuer E. J., Clegg L. X., Hayes R. B., Legler J. M., Prorok P. C., Ries L. A., Merrill R. M., Kaplan R. S. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999 Jun 16;91(12):1017–1024. doi: 10.1093/jnci/91.12.1017. [DOI] [PubMed] [Google Scholar]
  4. Jemal Ahmedin, Thomas Andrea, Murray Taylor, Thun Michael. Cancer statistics, 2002. CA Cancer J Clin. 2002 Jan-Feb;52(1):23–47. doi: 10.3322/canjclin.52.1.23. [DOI] [PubMed] [Google Scholar]
  5. Kim H. J., Fay M. P., Feuer E. J., Midthune D. N. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000 Feb 15;19(3):335–351. doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  6. Legler J. M., Feuer E. J., Potosky A. L., Merrill R. M., Kramer B. S. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control. 1998 Oct;9(5):519–527. doi: 10.1023/a:1008805718310. [DOI] [PubMed] [Google Scholar]
  7. Levy I. G., Iscoe N. A., Klotz L. H. Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ. 1998 Sep 8;159(5):509–513. [PMC free article] [PubMed] [Google Scholar]
  8. Mettlin C., Jones G., Averette H., Gusberg S. B., Murphy G. P. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993 Jan-Feb;43(1):42–46. doi: 10.3322/canjclin.43.1.42. [DOI] [PubMed] [Google Scholar]
  9. Nattinger A. B., McAuliffe T. L., Schapira M. M. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol. 1997 Aug;50(8):939–945. doi: 10.1016/s0895-4356(97)00099-1. [DOI] [PubMed] [Google Scholar]
  10. Oliver S. E., Gunnell D., Donovan J. L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000 May 20;355(9217):1788–1789. doi: 10.1016/s0140-6736(00)02269-8. [DOI] [PubMed] [Google Scholar]
  11. Sandblom G., Dufmats M., Nordenskjöld K., Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group. Cancer. 2000 Mar 15;88(6):1445–1453. doi: 10.1002/(sici)1097-0142(20000315)88:6<1445::aid-cncr24>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  12. Tarone R. E., Chu K. C., Brawley O. W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000 Mar;11(2):167–170. doi: 10.1097/00001648-200003000-00014. [DOI] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES